PCRX

Pacira BioSciences, Inc. (PCRX) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Pacira BioSciences, Inc. is a biopharmaceutical company focused on non-opioid pain therapies. Its core commercial products include EXPAREL (long-acting local analgesic), ZILRETTA (extended-release intra-articular injection for osteoarthritis), and iovera (cryoanalgesia device). In February 2025, the Company completed the acquisition of the remaining 81% equity interest in GQ Bio Therapeutics GmbH, securing full ownership of the high-capacity adenovirus (HCAd) gene therapy platform and advancing the development of PCRX-201.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 1% year-over-year. EXPAREL sales grew 3% driven by volume and price increases, while ZILRETTA sales declined 10% due to a sales force transition and lower kit volumes.
• Margin Expansion: Gross margin improved significantly by 8 percentage points to 80%. This was primarily due to the elimination of royalty payments to the Research Development Foundation (RDF) following a favorable court judgment in April 2025 (effective for Q1), lower inventory reserves, and improved manufacturing costs.
• Operating Expenses: Operating expenses increased to $166.9 million from $153.9 million. Notable increases included:
  • R&D: Up 39% to $25.3 million, driven by the start of the PCRX-201 Phase 2 ASCEND trial and other clinical studies.
  • Selling, General & Administrative (SG&A): Up 20% to $86.8 million, reflecting investments in marketing, market access, and reimbursement teams.
  • Legal Settlement: A one-time charge of $7.0 million was recorded for the settlement of patent infringement litigation with eVenus, Jiangsu Hengrui, and Fresenius.
• Acquisition Activity: The Company acquired GQ Bio for a total fair value of $38.7 million, recognizing $20.8 million in goodwill and $22.5 million in in-process R&D assets.

Guidance, Outlook, and Risks

• Legal Resolutions: The Company settled patent litigation regarding EXPAREL, agreeing to a license for generic entry in early 2030 (volume-limited) and 2039 (unlimited). Additionally, a court ruled the Company owes no royalties to RDF for EXPAREL manufactured under its enhanced process, eliminating a low single-digit royalty cost and creating a potential claim for repayment of up to $23.1 million paid under protest.
• Share Repurchase: In April 2025, the Board approved a new $300 million share repurchase program, replacing the previous $150 million authorization. The program expires December 31, 2026.
• Debt Obligations: The Company has $202.5 million in 0.750% Convertible Senior Notes due August 2025 and $287.5 million in 2.125% Convertible Senior Notes due May 2029. The 2025 Notes are currently convertible at any time. The Company maintains compliance with its Term Loan A covenants.
• Risks: Key risks include the successful integration of GQ Bio, the timing of generic entry for EXPAREL post-2030, the outcome of the PCRX-201 Phase 2 trial, and potential dilution from convertible note conversions.

Investor Verification Checklist

• Generic Entry Timeline: Verify the specific confidential dates and volume limits for the generic EXPAREL entry agreed upon in the April 2025 settlement.
• RDF Royalty Repayment: Monitor the status of the Company's claim for the repayment of up to $23.1 million in royalties paid to RDF under protest.
• 2025 Convertible Notes: Assess the likelihood of conversion or redemption of the $202.5 million notes maturing in August 2025, given the current stock price relative to the conversion price.
• PCRX-201 Clinical Data: Track the enrollment and topline results of the Phase 2 ASCEND study, expected before the end of 2026.
• ZILRETTA Sales Recovery: Evaluate whether ZILRETTA sales volumes stabilize following the sales force restructuring completed in Q4 2024.